Guillermo Garcia-Manero
Corporate Officer/Principal chez Amphivena Therapeutics, Inc.
Postes actifs de Guillermo Garcia-Manero
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | - | - |
Historique de carrière de Guillermo Garcia-Manero
Statistiques
Internationale
| Etats-Unis | 2 |
Opérationnelle
| Corporate Officer/Principal | 1 |
Sectorielle
| Retail Trade | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Retail Trade |
- Bourse
- Insiders
- Guillermo Garcia-Manero
- Expérience
